Chines biopharmaceutical contract manufacturing market is projected of ~13%, By Roots

Roots Analysis has done a detailed study on China Biopharmaceutical Contract Manufacturing Market, 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

 

To order this 250+ page report, which features 100+ figures and 120+ tables, please visit this link

 

Key Market Insights

  • Over 35 CMOs / CDMOs in China claim to offer a variety of services related to development and manufacturing of a wide range of biotherapeutic products
  • Several players provide one-stop solutions and are capable of operating at various scales; the landscape includes a mix of both established players and new entrants
  • In order to cater to the evolving needs of clients / sponsors, CMOs have established facilities across different regions of China; Eastern China, with the maximum number of sites, has emerged as a manufacturing hub
  • With over 80 deals inked in past five years, there has been a surge in the partnership activity within this domain; majority of these collaborations were signed for the development and manufacturing of antibody-based products
  • Big pharma players have also made significant investments in this region, including establishing new facilities, expanding existing R&D centers and growing manufacturing facilities, focused on biotherapeutics
  • We expect global biopharmaceutical developers to continue to outsource their manufacturing operations to China in the long term; we anticipate the CMO industry in the region to grow at an annualized rate of ~13%, till 2030

For more information, please visit https://www.rootsanalysis.com/reports/view_document/china-biopharmaceutical-contract-manufacturing/313.html

 

Table of Contents

 

  1. PREFACE
    1.1. Scope of the Report
    1.2.       Research Methodology
    1.3.       Chapter Outlines

    2.         EXECUTIVE SUMMARY

  2. INTRODUCTION
    3.1. Chapter Overview

 

  • Overview of Biopharmaceuticals

 

3.3.       Manufacturing of Biopharmaceuticals

3.3.1.    Types of Expression Systems Used

3.3.1.1. Bacterial Expression Systems

3.3.1.2. Yeast Expression Systems

3.3.1.3. Insect Expression Systems

3.3.1.4. Plant Expression Systems

3.3.1.5. Mammalian Expression Systems

3.3.1.6. Fungal Expression Systems

 

3.3.2.    Processing Steps

3.3.2.1. Upstream Processing

3.3.2.2. Downstream Processing

 

3.4.       Overview of Contract Manufacturing

3.4.1.    Contract Manufacturing Scenario in China

3.5.       Need for Outsourcing in the Biopharmaceutical Industry

3.5.1.    Biopharmaceutical Outsourcing in China: Regulatory Scenario

 

3.6.       Commonly Outsourced Operations in the Biopharmaceutical Industry

 

3.7.       Basic Guidelines for Selecting a CMO Partner

3.8.       Advantages of Outsourcing Manufacturing Services

3.8.1.    Benefits of Engaging Chinese Contract Service Providers

 

3.9.       Risks and Challenges Associated with Biopharmaceutical Contract Manufacturing

3.9.1.    Challenges Associated with Engaging Chinese Contract Service Providers

3.10.     Future Perspective

 

  1. CASE STUDY: COMPARISON OF SMALL MOLECULES AND LARGE MOLECULES

4.1.       Chapter Overview

 

4.2.       Small Molecule and Large Molecule Drugs / Therapies

4.2.1.    Comparison of Key Characteristics

4.2.2.    Comparison of Manufacturing Processes

4.2.3.    Comparison of Key Manufacturing-Related Challenges

           

  1. COMPETITIVE LANDSCAPE

5.1.       Chapter Overview

 

5.2.       Chinese Biopharmaceutical Contract Manufacturers: Overall Market Landscape

5.2.1.    Analysis by Year of Establishment

5.2.2.    Analysis by Company Size

5.2.3.    Analysis by Scale of Operation

5.2.4.    Analysis by Location of Headquarters

5.2.5.    Analysis by Location of Manufacturing Facilities

5.2.6.    Analysis by Type of Product

5.2.7.    Analysis by Types of Services Offered

5.2.8.    Analysis by Type of Biologic

5.2.9.    Analysis by Expression System Used

5.2.10.  Analysis by Type of Bioreactor Used

5.2.11.  Analysis by Mode of Operation of Bioreactor

5.2.12.  Analysis by Packaging Form Used

5.2.13.  Analysis by Regulatory Accreditations / Certifications

           

  1. COMPANY PROFILES

6.1        Chapter Overview

 

6.2        ChemPartner Biologics

6.2.1.    Company Overview

6.2.2.    Service Portfolio

6.2.3.    Manufacturing Facilities and Capabilities

6.2.4.    Recent Developments and Future Outlook

 

6.3.       JHL Biotech

6.3.1.    Company Overview

6.3.2.    Service Portfolio

6.3.3.    Manufacturing Facilities and Capabilities

6.3.4.    Recent Developments and Future Outlook

 

6.4.       JOINN Biologics

6.4.1.    Company Overview

6.4.2.    Service Portfolio

6.4.3.    Manufacturing Facilities and Capabilities

6.4.4.    Recent Developments and Future Outlook

 

6.5        MabPlex

6.5.1.    Company Overview

6.5.2.    Service Portfolio

6.5.3.    Manufacturing Facilities and Capabilities

6.5.4.    Recent Developments and Future Outlook

 

6.6.       Mycenax Biotech

6.6.1.    Company Overview

6.6.2.    Service Portfolio

6.6.3.    Manufacturing Facilities and Capabilities

6.6.4.    Recent Developments and Future Outlook

 

6.7.       WuXi AppTec

6.7.1.    Company Overview

6.7.2.    Financial Information

6.7.3.    Service Portfolio

6.7.4.    Manufacturing Facilities and Capabilities

6.7.5.    Recent Developments and Future Outlook

 

  1. PARTNERSHIPS

7.1        Chapter Overview

 

7.2.       Partnership Models

 

7.3.       Chinese Biopharmaceutical Contract Manufacturers: Recent Partnerships

7.3.1.    Analysis by Year of Partnership

7.3.2.    Analysis by Type of Partnership

7.3.3.    Analysis by Scale of Operation

7.3.4.    Analysis by Type of Biologic

7.3.5.    Analysis by Focus Area

7.3.6.    Analysis by Therapeutic Area

7.3.7.    Most Active Players: Analysis by Number of Partnerships

7.3.8.    Geographical Analysis

7.3.9.    Geographical Distribution by Number of Partnerships

7.3.10.  Intercontinental and Intracontinental Agreements

 

  1. RECENT EXPANSIONS

8.1.       Chapter Overview

 

8.2.       Chinese Biopharmaceutical Contract Manufacturers: Recent Expansions

8.2.1.    Analysis by Year of Expansion

8.2.2.    Analysis by Type of Expansion

8.2.3.    Analysis by Scale of Operation

8.2.4.    Analysis by Type of Biologic

8.2.5.    Analysis by Location of Expansion Project

8.2.6.    Analysis by Capacity of Expanded Facility

8.2.7.    Most Active Players: Analysis by Number of Expansions

8.2.8.    Analysis by Region

 

  1. CLINICAL TRIAL ANALYSIS

9.1.       Chapter Overview

 

9.2.       Scope and Methodology

 

9.3        Clinical Trial Analysis: Biologic Drugs

9.3.1.    Analysis by Trial Registration Year

9.3.2.    Analysis by Trial Phase

9.3.3.    Analysis by Trial Status

9.3.4.    Geographical Analysis by Number of Clinical Trials

9.3.5.    Geographical Analysis by Enrolled Patient Population

9.3.6.    Analysis of Enrolled Patient Population by Trial Registration Year

9.3.7.    Analysis of Enrolled Patient Population by Trial Phase

9.3.8.    Analysis by Type of Sponsor / Collaborator

9.3.9.    Most Active Players: Analysis by Number of Registered Trials

9.3.10.  Analysis by Clinical Trial Center

  1. REGIONAL CAPABILITY ANALYSIS

10.1.     Chapter Overview

10.2.     Assumptions and Key Parameters

10.3.     Overall Landscape of Chinese Biopharmaceutical Contract Manufacturers

10.4.     Regional Capability Analysis: Biopharmaceuticals Contract Manufacturers in Northern China

10.5.     Regional Capability Analysis: Biopharmaceuticals Contract Manufacturers in Eastern China

10.6.     Regional Capability Analysis: Biopharmaceuticals Contract Manufacturers in Central China

10.7.     Regional Capability Analysis: Biopharmaceuticals Contract Manufacturers in Southern China

 

  1. CAPACITY ANALYSIS

11.1.     Chapter Overview

 

11.2.     Assumptions and Methodology

 

11.3.     Chinese Biopharmaceutical Contract Manufactures: Installed Capacity

11.3.1.  Analysis by Company Size

11.3.2.  Analysis by Scale of Operation

11.3.3.  Analysis by Expression System Used

11.3.4.  Analysis by Location of Manufacturing Facility

11.3.5.  Analysis by Company Size and Location of Manufacturing Facility

11.3.6.  Analysis by Company Size and Location of Manufacturing Facility

 

11.4.     Concluding Remarks

 

  1. BIG PHARMA BIOPHARMACEUTICAL MANUFACTURING INITIATIVES IN CHINA

12.1.     Chapter Overview

 

12.2.     List of Biopharmaceutical R&D and Manufacturing Initiatives of Big Pharma Players in China

12.2.1.  Analysis by Number of Initiatives

12.2.2.  Analysis by Year of Initiative

12.2.3.  Analysis by Company and Year of Initiative

 

12.2.4.  Analysis by Type of Initiative

12.2.5.  Analysis by Type of Biologic

 

12.3.     Competitive Benchmarking of Big Pharmaceutical Players

12.3.1.  Harvey Ball Analysis: Big Pharma Investment Summary

12.3.2.  Geographical Analysis by Investment Made

 

  1. MAKE VERSUS BUY DECISION MAKING FRAMEWORK

13.1.     Chapter Overview

13.2.     Assumptions and Key Parameters

13.3.     Chines Biopharmaceutical Contract Manufacturers: Make versus Buy Decision Making

13.4.     Conclusion                               

 

  1. MARKET SIZING AND OPPORTUNITY ANALYSIS

14.1.     Chapter Overview

 

14.2.     Key Assumptions and Forecast Methodology

14.3.     Biopharmaceutical Contract Manufacturing Market in China, 2020-2030

14.3.1.  Biopharmaceutical Contract Manufacturing Market in China for APIs, 2020-2030

14.3.2.  Biopharmaceutical Contract Manufacturing Market in China for FDFs, 2020-2030

 

14.4.     Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Distribution by Expression System Used

14.4.1.  Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Mammalian Systems

14.4.2.  Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Microbial Systems                   

14.4.3.  Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Other Expression Systems

 

14.5.     Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Distribution by Scale of Operation

14.5.1.  Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Preclinical / Clinical Scale Operations

14.5.2.  Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Commercial Operations

           

14.6.     Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Distribution by Size of Manufacturers

14.6.1.  Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Small Companies

14.6.2.  Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Mid-sized Companies

14.6.3.  Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Large and Very Large Companies

 

14.7.     Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Distribution by Type of Biologic

14.7.1.  Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Antibodies

14.7.2.  Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Vaccines

14.7.3.  Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Other Biologics

 

  1. COVID-19 Impact on China Biopharmaceutical CMO Market

15.1.     Chapter Overview

15.2.     Evaluation of Impact of COVID-19 Outbreak

 

15.2.1.   Initiatives and Opinions of Key Players

15.2.1.1. WuXi AppTec

 

15.2.1.2. Boehringer Ingelheim

15.2.1.3. GE Healthcare

15.2.1.4. Lonza

15.2.1.5. AmbioPharm

 

15.2.2. Impact of China Biopharmaceutical Contract Manufacturing Market

15.3.     Key Strategies to Adopt: A Bird’s Eye View

15.3.1.  Immediate Steps

15.3.2.  Short / Long-Term Steps

 

  1. SWOT ANALYSIS

16.1.     Chapter Overview

16.2.     Strengths

16.3.     Weaknesses

16.4.     Opportunities

16.5.     Threats

16.6.     Comparison of SWOT Factors

16.7.     Concluding Remarks

 

  1. FUTURE OF THE CHINA BIOPHARMACEUTICAL CMO MARKET

17.1.     Chapter Overview

17.2.     Outsourcing Activities Anticipated to Increase in Future

17.3.     Shift from One-time Contracts to Strategic Partnerships

17.4.     Adoption of Innovative Technologies

17.4.1.  Single Use Bioreactors

17.4.2.  Novel Bioprocessing Techniques

17.4.3.  Bioprocess Automation

 

17.5.     Growing Popularity of the Quality by Design Principle in Bioprocessing

17.6.     Increasing Focus on Niche Therapeutic Areas

17.7.     Biosimilars Market to Contribute to Contract Service Revenues

17.8.     Capability and Facility Expansions to Establish One Stop Shop Expertise

17.9.     Increase in Financial In-flow and Outsourcing Budgets

17.10.   Challenges Faced by Sponsors and Service Providers

17.10.1. Concerns Associated with Single Use Systems

17.10.2. Issues Related to Capacity Fluctuations

 

17.11.   Concluding Remarks

  1. INTERVIEW / SURVEY TRANSCRIPT(S)
  2. APPENDIX 1: TABULATED DATA
  3. APPENDIX 2: LIST OF COMPANIES AND ORGANISTIONS

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Be the first to comment

Please check your e-mail for a link to activate your account.

connect